Samantaray A, Chandra A, Panigrahi S. Amiodarone for the prevention of reperfusion ventricular fibrillation.
J Cardiothorac Vasc Anesth 2009;
24:239-43. [PMID:
19800815 DOI:
10.1053/j.jvca.2009.07.007]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2009] [Indexed: 11/11/2022]
Abstract
OBJECTIVE
The purpose of this study was to evaluate the efficacy of prophylactic single-dose amiodarone administered through the pump circuit before releasing the aortic cross-clamp (ACC) in preventing the occurrence of reperfusion ventricular fibrillation (RVF).
DESIGN
A prospective, randomized double-blind, placebo-controlled efficacy study.
SETTING
A tertiary level teaching hospital.
INTERVENTION
Seventeen patients received 150 mg of amiodarone in 10 mL of normal saline by way of the pump 3 minutes before releasing the ACC, and a control group of 17 patients received 10 mL of normal saline.
MEASUREMENT AND MAIN RESULTS
The primary outcome of the study was the incidence of ventricular fibrillation requiring defibrillation during the 30-minute period after myocardial reperfusion. A large decrease in RVF (65% to 18%) was observed in the amiodarone-treated group with the number needed to treat only 2.1.The myocardial performance in terms of cardiac output was better in the amiodarone group; this could be attributed to the lower incidence of RVF and subsequent direct current shock therapy.
CONCLUSIONS
The observations showed that single-dose prophylactic amiodarone administered through the pump circuit 3 minutes before ACC release was an effective therapy to reduce the incidence of post-ACC release ventricular arrhythmias.
Collapse